FindTrial
Sign In

Comparison of two anaesthetic drug as sedative for ERCP

Etomidate versus propofol as sedative for ERCP - A prospective randomized controlled trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/07/043892
Enrollment
100
Registered
2022-07-11
Start date
Unknown
Completion date
Unknown
Last updated
2022-08-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K87- Disorders of gallbladder, biliarytract and pancreas in diseases classified elsewhere Health Condition 2: O- Medical and Surgical

Interventions

Intervention1: Etomidate infusion: received etomidate 0.15-0.2 mg/kg over 60 seconds followed by 5 -10 mcg/kg/min through infusion pump. Control Intervention1: Propofol: received propofol 1.5-2 mg/kg

Sponsors

Nitin mantri
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: ASA grade I -II undergoing ERCP in Institute of Liver and Biliary Sciences New Delhi

Exclusion criteria

Exclusion criteria: 1.Patient refusal 2.Chronic sedative or opioid analgesic use 3.Known allergy to the study drugs 4.Uncontrolled Hypertension 5.Uncontrolled Diabetes 6.Presence of Cirrhosis (on imaging +/- histology) 7.Post liver transplant recipients 8.Heart failure (ejection fraction 9.Severe respiratory disease (FEV1 10.Porphyria 11.Pre-existing epilepsy 12.Pregnancy 13.Lactation 14.Procedure more than 60 min 15.Patients with known adrenocortical insufficiency

Design outcomes

Primary

MeasureTime frame
To determine no.of transient hypotension in both groups. Timepoint: 3 months—

Secondary

MeasureTime frame
To determine no. Of transient hypoxia in both groups Induction time Recovery time Any adverse effectsTimepoint: 3 months—

Countries

India

Contacts

Public ContactNitin Mantri

ILBS Hospital,New Delhi

uddh1989@gmail.com8861987684

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026